Ermioni Kalfopoulou

Dr. Ermioni Kalfopoulou

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Ermioni KalfopoulouErmioni Kalfopoulou
Ermioni Kalfopoulou
JHJohannes Huebner
Johannes Huebner
Enterococci are the second most common Gram-positive pathogen responsible for nosocomial infections. Due to the limited number of new antibiotics that reach the medical practice and the resistance of enterococci to the current antibiotic options, passive and active immunotherapies have emerged as a potential prevention and/or treatment strategy against this opportunistic pathogen. In this review, we explore the pathogenicity of these bacteria and their interaction with the host immune response. We provide an overview of the capsular polysaccharides and surface-associated proteins that have been described as potential antigens in anti-enterococcal vaccine formulations. In addition, we describe the current status in vaccine development against enterococci and address the importance and the current advances toward the development of well-defined vaccines with broad coverage against enterococci.

4 May 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
DLDiana Laverde
Diana Laverde
FRFelipe Romero-Saavedra
Felipe Romero-Saavedra
DADmitry A. Argunov
Dmitry A. Argunov
JEJacopo Enotarpi
Jacopo Enotarpi
VKVadim B. Krylov
Vadim B. Krylov
JHJohannes Huebner
Johannes Huebner

9 July 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FRF Romero-Saavedra
F Romero-Saavedra
DLD Laverde
D Laverde
Ermioni KalfopoulouErmioni Kalfopoulou
Ermioni Kalfopoulou
CMCecilia Martini
Cecilia Martini
RTRiccardo Torelli
Riccardo Torelli
JHJ Huebner
J Huebner
Enterococci have emerged as important nosocomial pathogens due to their resistance to the most commonly used antibiotics. Alternative treatments or prevention options are aimed at polysaccharides and surface-related proteins that play important roles in pathogenesis. Previously, we have shown that 2 Enterococcus faecium proteins, the secreted antigen A and the peptidyl-prolyl cis-trans isomerase, as well as the Enterococcus faecalis polysaccharide diheteroglycan, are able to induce opsonic and cross-protective antibodies. Here, we evaluate the use of glycoconjugates consisting of these proteins and an enterococcal polysaccharide to develop a vaccine with broader strain coverage. Diheteroglycan was conjugated to these 2 enterococcal proteins. Rabbit sera raised against these glycoconjugates showed Immunoglobulin G titers against the corresponding conjugate, as well as against the respective protein and carbohydrate antigens. Effective opsonophagocytic killing for the 2 sera was observed against different E. faecalis and E. faecium strains. Enzyme-linked immunosorbent assays against whole bacterial cells showed immune recognition of 22 enterococcal strains by the sera. Moreover, the sera conferred protection against E. faecalis and E. faecium strains in a mouse infection model. Our results suggest that these glycoconjugates are promising candidates for vaccine formulations with a broader coverage against these nosocomial pathogens and that the evaluated proteins are potential carrier proteins.

1 September 2019 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
Ermioni KalfopoulouErmioni Kalfopoulou
Ermioni Kalfopoulou
DLDiana Laverde
Diana Laverde
KMKarmela Miklic
Karmela Miklic
FRFelipe Romero-Saavedra
Felipe Romero-Saavedra
SMSuzana Malic
Suzana Malic
JHJohannes Huebner
Johannes Huebner
Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species.